An Early Phase 1 interventional study of Simvastatin in Celiac Disease, sponsored by Entero Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-05.
Sponsored by Entero Therapeutics · Early Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.
Among the 103 studies in Celiac Disease with a site in United States, this one is the 38th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2016, is one of 16 in phase 1, and was the 42nd registered.
352 studies on the registry are indexed under Celiac Disease; 77 are open to participants now.
Browse Celiac Disease studies →16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:
Nielsen Fernandez-Becker · Sites in United States
Ages 18+
Chugai Pharmaceutical · Sites in United States, Australia, New Zealand
Ages 18–75
Joined Bio · Sites in United States
Ages 18–90 · Healthy volunteers
Columbia University · Sites in United States
Ages 18–75
Luventix, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 22 · Phase 3 2 · Phase 4 2
First in 1995; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 50 across 214 interventional studies indexed under Celiac Disease.
Median enrollment 46 across the 68 interventional studies, 175 across the 35 observational. Of the 74 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 103 have an industry lead sponsor. The 10 most frequent:
Entero Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Entero Therapeutics has 3 studies filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Celiac Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06310291Barinthus BiotherapeuticsVTP-1000 in Adults With Celiac Disease | 2026-11 |
| NCT06908057AdventHealth Translational Research InstituteAccessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D) | 2026-12 |
| NCT05680012University of ChicagoTissue Destruction and Healing in Celiac Disease | 2027-05-01 |
| NCT07377565Nielsen Fernandez-BeckerA First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease | 2027-06-01 |
| NCT07239336Chugai PharmaceuticalStudy of DONQ52 in Active Celiac Disease | 2027-06-15 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Celiac Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To study the correlation between simvastatin metabolism by the enterocyte and the histologic state of the intestine in treated celiac disease.
A cross sectional design incorporating subjects with active celiac disease and healed celiac disease (based on clinically-obtained biopsies); and healthy individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Simvastatin tablet, 20 mg, one time by mouth
Drug: Simvastatin
20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
Also known as: Zocor
Compare simvastatin metabolism with intestinal biopsies
Time frame: Within one month of visit
Villous height and crypt depth
As measured in intestinal biopsies
Time frame: Within 1 month of visit
Dietary interview
To determine whether the patient is strictly adherent, mostly adherent or non-adherent to a gluten-free diet
Time frame: At initial visit
Urinalysis
Looking for traces of gluten peptides
Time frame: Prior to administration of simvastatin and at the 3-hour mark
Serologic testing
tTG IgA titer level determination
Time frame: Prior to administration of simvastatin
DNA sampling
Genetic testing associated with celiac disease (DQ2 and DQ8)
Time frame: Prior to administration of simvastatin
Plan to share: No
The record gives a start of Mar 2016, a primary completion of Jan 2019 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simvastatin
Entero Therapeutics